Skip to content
RDL
Network
Ekosistem
Uygulama değiştir
EN
Hakkımızda
SSS
Giriş yap
Başla
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors — Matthew D. Cullen (2008) | RDL Network
Back
Cite
Save
Save for later
Share
Home
Publications
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors
Shared by
De Clercq Erik
KU Leuven
Investigation of the alkenyldiarylmethane non-nucleoside reverse transcriptase inhibitors as potential cAMP phosphodiesterase-4B2 inhibitors
Article
2008
en
Authors
+6 more
MC
Matthew D. Cullen
YC
York-Fong Cheung
MH
Miles D. Houslay
Discussion
(0)
Sign in
to like and join the discussion.
No comments yet. Be the first to comment.
Related publications
Article
2017
Designing Novel Hydrazinecarbothioamides as Potential HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
Hong Yin
,
Zheng-Yong Wan
,
Ge Meng
,
Fen‐Er Chen
,
De Clercq Erik
,
and Christophe Pannecouque
Article
1994
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
De Clercq Erik
Article
2004
Design, Synthesis, Anti-HIV Activities, and Metabolic Stabilities of Alkenyldiarylmethane (ADAM) Non-nucleoside Reverse Transcriptase Inhibitors
Maximilian A. Silvestri
,
Muthukaman Nagarajan
,
De Clercq Erik
,
Christophe Pannecouque
,
Mark Cushman
Article
2005
Synthesis, Anti-HIV Activity, and Metabolic Stability of New Alkenyldiarylmethane HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors
Bo‐Liang Deng
,
Tracy L. Hartman
,
Robert W. Buckheit
,
Christophe Pannecouque
,
De Clercq Erik
,
Phillip E. Fanwick
,
Mark Cushman
Article
2007
Synthesis and Biological Evaluation of Alkenyldiarylmethane HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors That Possess Increased Hydrolytic Stability
Matthew D. Cullen
,
Bo‐Liang Deng
,
Tracy L. Hartman
,
Karen Watson
,
Robert W. Buckheit
,
Christophe Pannecouque
,
De Clercq Erik
,
Mark Cushman
Discussion(0)
No comments yet. Be the first to comment.